OM Investors Have Opportunity to Lead Outset Medical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Outset Medical, Inc. for alleged violations of securities laws, specifically related to misleading statements about its Tablo products [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Outset made false and misleading statements regarding its Tablo products, which were marketed for continuous renal replacement therapy without FDA approval [4]. - The class period for the lawsuit is defined as from August 1, 2022, to August 7, 2024, during which investors are encouraged to participate if they suffered losses [2]. - The Schall Law Firm is representing investors and has not yet certified the class, meaning potential participants are not currently represented by an attorney [3]. Group 2: Company Operations - Outset is expected to submit a 510(k) application to the FDA for its Tablo products, but sales are likely to be halted until this application is approved [4]. - The company reportedly lacks the sales force necessary to effectively ramp up sales of the Tablo products, contributing to the misleading nature of its public statements [4]. - The revelation of the truth about Outset's operations has led to investor damages, indicating a significant impact on the company's market perception [4].